Loading
If this is the first time anyone has visited this substance, we may be fetching live data from TGA Product Information, PBS, and state framework sources — that can take up to a minute. Cached substances load in a second or two.
Select your state to see jurisdictional framework, reporting obligations, and authority links. Substance information above is the same in every state.
A plain-language summary of the cited sources below. Informational only — not medical advice.
Oxycodone is a strong pain medicine from the opioid family. It works by attaching to specific sites in the brain and spinal cord called μ-opioid receptors, which are the same receptors that respond to the body's own natural pain-relieving chemicals. When oxycodone binds to these receptors, it reduces the release of pain signals between nerve cells, which is why it can provide powerful pain relief. The medicine also affects reward pathways in the brain, which is why opioids carry a risk of dependence and why tolerance can develop over time—meaning higher doses may be needed to achieve the same level of pain control.
Doctors prescribe oxycodone for severe pain when other treatments haven't worked, can't be used, or aren't suitable. It comes in different forms: immediate-release versions that work quickly and wear off in two to three hours, and controlled-release versions that last longer, around four and a half hours. Your family member's body breaks down oxycodone mainly through liver enzymes in the CYP3A family, with a smaller contribution from an enzyme called CYP2D6.
The most common side effects are nausea, vomiting, constipation, drowsiness, and unusual tiredness or weakness. These can be troublesome but are often manageable with support from the prescribing doctor. More serious risks include respiratory depression—where breathing becomes dangerously slow or shallow—which is the most critical concern with any opioid. In children, seizures can occur. Very large doses can lead to further slowing of breathing, low blood pressure, circulatory problems, and deepening loss of consciousness. Some people also experience raised pressure inside the skull.
Oxycodone should not be used in people who are allergic to opioids, or who have acute breathing problems, certain severe lung or heart conditions, brain tumours, head injuries, increased pressure in the brain or spinal fluid, severe depression of the central nervous system, seizure disorders, delirium tremens, or suspected acute abdominal conditions. It also must not be taken at the same time as certain antidepressants called MAOIs, or within 14 days of stopping them.
Severe pain Clinical criteria: The treatment must be for short term therapy of acute severe pain, AND Patient must have had or would have inadequate pain management with maximum tolerated doses of non-opioid analgesics; OR Patient must be unable to use non-opioid analgesics due to contraindications or intolerance.
Severe disabling pain Clinical criteria: Patient must have had or would have inadequate pain management with maximum tolerated doses of non-opioid or other opioid analgesics; OR Patient must be unable to use non-opioid or other opioid analgesics due to contraindications or intolerance. Treatment criteria: Patient must be undergoing palliative care. Authority requests for treatment duration up to 1 month may be requested through the Online PBS Authorities system or by calling Services Australia. Authority requests extending treatment duration beyond 1 month may be requested through the Online PBS Authorities system or in writing and must not provide a treatment duration exceeding 3 months (quantity sufficient for up to 1 month treatment and sufficient repeats).
“Oxycodone is an opioid agonist and binds to μ− (mu) and more weakly to κ− (kappa) and δ− (delta) opioid receptor subtypes.”
“The elimination half-life is reported to be 2 to 4 hours.”
“It is extensively metabolised to noroxycodone via cytochrome P450 isoenzymes of the CYP3A family and, to a lesser extent, to oxymorphone via CYP2D6.”
A plain-language summary of the cited sources below. Informational only — not medical advice.
Oxycodone is a semi-synthetic opioid and highly selective full agonist of the μ-opioid receptor, with lower affinity for δ- and κ-opioid receptors. Analgesic effects are mediated via μ-opioid receptor activation in the periaqueductal grey and rostral ventromedial medulla; reward and addiction liability arise from activation in the mesolimbic pathway, including the ventral tegmental area and nucleus accumbens. Tolerance develops through receptor downregulation, cellular adaptation including cAMP upregulation, and system-level neural changes such as ΔFosB induction. TGA-approved indications are short-term management of severe pain for which other treatment options have failed, are contraindicated, not tolerated, or otherwise inappropriate, as well as severe disabling pain and chronic severe pain.
Oxycodone is extensively metabolised to noroxycodone via CYP3A isoenzymes and to a lesser extent to oxymorphone via CYP2D6. The elimination half-life is 2–4 hours for immediate-release formulations and 4.5 hours for controlled-release preparations. Common adverse effects include nausea, vomiting, constipation, drowsiness, and unusual tiredness or weakness. Serious adverse effects include respiratory depression, raised intracranial pressure in some patients, convulsions in infants and children, and death from respiratory failure; larger doses produce hypotension with circulatory failure and deepening coma. Contraindications include hypersensitivity to opiate narcotics, acute respiratory disease, cor pulmonale, cardiac arrhythmias, bronchial asthma, acute alcoholism, brain tumour, head injuries, increased cerebrospinal or intracranial pressure, severe CNS depression, severe respiratory disease and respiratory depression, convulsive disorders, delirium tremens, suspected surgical abdomen, and concomitant MAOIs or within 14 days of such therapy.
Working under the parallel aged-care framework? Aged-care equivalent →
Chronic severe pain Clinical criteria: Treatment Phase: Initial PBS treatment after 1 June 2020 where patient has been treated with opioids for less than 12 months The condition must require daily, continuous, long term opioid treatment, AND Patient must have cancer pain; OR Patient must have had or would have inadequate pain management with maximum tolerated doses of non-opioid or other opioid analgesics; OR Patient must be unable to use non-opioid or other opioid analgesics due to contraindications or intolerance. Authorities for increased maximum quantities and/or repeats under this restriction must only be considered for chronic severe disabling pain where the total duration of non-PBS and PBS opioid analgesic treatment is less than 12 months. Authority requests extending treatment duration up to 1 month may be requested through the Online PBS Authorities system or by calling Services Australia. Authority requests extending treatment duration beyond 1 month may be requested through the Online PBS Authorities system or in writing and must not provide a treatment duration exceeding 3 months (quantity sufficient for up to 1 month treatment and sufficient repeats).
Curated subset. The full adverse-effect list is in the TGA Product Information; click any citation above to open it.